Array
(
[1563353281] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1563353371] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563354752] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1563356246] => Array
(
[wordfence_processAttackData] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1563356373] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1563358511] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563358552] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563365552] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563370326] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1563371074] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563376673] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1563379624] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563382611] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563433712] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1563436845] => Array
(
[publish_future_post] => Array
(
[cb6ae981f1c892db2cf1bf6c13ed9dc4] => Array
(
[schedule] =>
[args] => Array
(
[0] => 454524
)
)
)
)
[1563804000] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1569362425] => Array
(
[publish_future_post] => Array
(
[6c2e8ec23ac9ad461e173651b5bf0c29] => Array
(
[schedule] =>
[args] => Array
(
[0] => 439567
)
)
)
)
[1569362446] => Array
(
[publish_future_post] => Array
(
[3139b3d670d2f3719b91143334fe5bbc] => Array
(
[schedule] =>
[args] => Array
(
[0] => 448864
)
)
)
)
[1569448832] => Array
(
[publish_future_post] => Array
(
[4a517b3a869bc596a52baac19dc2a199] => Array
(
[schedule] =>
[args] => Array
(
[0] => 451706
)
)
)
)
[1574550046] => Array
(
[publish_future_post] => Array
(
[892de8dabd22f7830c930f8117a13574] => Array
(
[schedule] =>
[args] => Array
(
[0] => 454502
)
)
)
)
[1580169600] => Array
(
[publish_future_post] => Array
(
[2d492587fa52e9c78f7043ddf937b0a1] => Array
(
[schedule] =>
[args] => Array
(
[0] => 18611
)
)
[dea3edad73162f380bc9dc44fa3407bf] => Array
(
[schedule] =>
[args] => Array
(
[0] => 19670
)
)
[2caa9c58a241c4f77a6856802c1b43fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 20734
)
)
[307b37ba29b8cd716eafa809661756e3] => Array
(
[schedule] =>
[args] => Array
(
[0] => 22852
)
)
[365be9eba8e62abb0c0d4bfe013a2687] => Array
(
[schedule] =>
[args] => Array
(
[0] => 23918
)
)
[0e942b20ffb9550322105263ad82126f] => Array
(
[schedule] =>
[args] => Array
(
[0] => 24977
)
)
[661c5eb39689fe2133ff7986ac6628fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 26036
)
)
[75562b264e355915e4dea97042a28f7e] => Array
(
[schedule] =>
[args] => Array
(
[0] => 27095
)
)
[11cf4e8a6f842b0115881551a29c47f6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 28154
)
)
[55a38aaca11da398c854cb29a7d4f5e6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 30272
)
)
[f8cbc904676c235c7057ec965c01c023] => Array
(
[schedule] =>
[args] => Array
(
[0] => 32390
)
)
)
)
[1583794819] => Array
(
[publish_future_post] => Array
(
[9d993985746691420cd7524448c48a23] => Array
(
[schedule] =>
[args] => Array
(
[0] => 448880
)
)
)
)
)
Etiquetas: 30 septiembre 2010, 30/09/2010, Adefarma, Agosto de 2010, Alertas de la Agencia Española de Medicamentos, Asistencia, Asociación de empresarios de farmacia de Madrid, consumo, Demanda, GMR, Indicadores Farmacéuticos, Informe de evolución, Legislación, Madrid, Medicamento, medicamentos, Nuevos medicamentos, principios activos, Productos sanitarios, Recetas facturadas, Sanidad, Saud, SNS.
Etiquetas: 2006, 28 septiembre de 2006, Adefarma, Agosto, El gasto farmacéutico en la Comunidad de Madrid, evolución, Gasto farmacéutico, Gasto Medio por Receta Facturada, Gasto total farmacéutico en España, Indicadores Farmacéuticos, Informe de evolución, Legislación y desarrollo legislativo, Madrid, Nuevos medicamentos y principios activos, Nº recetas, Principales indicadores del consumo y demanda de medicamentos, Recetas facturadas, salud, Sanidad.
Etiquetas: 31 agosto de 2006, Adefarma, Alertas de la AEMPS, Biocidas, Consumo de medicamentos por habitante en la Comunidad de Madrid, evolución, Farmacovigilancia, Gasto farmacéutico, Gasto farmacéutico en la Comunidad de Madrid, Gasto medio por receta, Indicadores Farmacéuticos, Informe de evolución, julio 2006, Legislación y desarrollo legislativo, Madrid, Nuevos medicamentos y principios activos, Principales indicadores del consumo y demanda de medicamentos, Productos cosméticos, Productos de higiene, Receta Oficial, salud, Sanidad, SNS.
Etiquetas: 1 de septiembre de 2008, Adefarma, AEMPS, Agencia española de medicamentos y productos sanitarios, Asociaciones de Pacientes, CC OO, CEAFAEF, Comercialización, Comunidad de Madrid, consumo, Contaminación de Viracept, Convenio colectivo marco para oficinas de farmacia, Daiichi Sankyo, Demanda, España, Etiquetado, evolución, Farmacéuticos, Fed. Servicios Públicos UGT, Federación Empresarial de Farmacéuticos Españoles, Federación Nacional de Oficinas de Farmacia, FEFE, FENOFAR, Gasto medio, Gastos financiados, Indicadores, Informe de evolución, Instituto Nacional de Estadistica, Julio 2008, Legislación, Madrid, Marcas iguales de medicamentos, Medicamento veterinario, medicamentos, Medicamentos de uso humano, Mesa Negociadora del Convenio Colectivo para las Oficinas de Farmacia, Ministerio de Sanidad y Consumo, Natalizumab, Nelfinavir, Prestación farmacéutica, Productos cosméticos, Profesionales sanitarios, Prospecto, Prueba de compresión de prospectos, Ranbaxy Laboratories, Receta, Recetas facturadas, salud, Sanidad, Sentencia, Servicio Madrileño de Salud.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x.gif)